Ironwood Pharmaceuticals (IRWD) : Investors lapped up stocks on upticks to the tune of $6.12 million in the Wednesdays trading session. The trading value on downticks was comparatively at $2 million and the uptick to downtick ratio of 3.06 indicates continuous buying by the bulls. The net money flow into the stock was $4.12 million. Upticks saw transactions worth $4.16 clearly indicating buying by large investors. The total money flow for block trades stood at $4.16 million, which is a positive for the stock in the long-term. Ironwood Pharmaceuticals (IRWD) fell $0.22 during the day at $15.88, a drop of -1.37% over the previous days close. However, for the week, the stock is 1.02%, compared to the previous week.
Shares of Ironwood Pharmaceuticals, Inc. rose by 1.86% in the last five trading days and 16.59% for the last 4 weeks. Ironwood Pharmaceuticals, Inc. is up 22.44% in the last 3-month period. Year-to-Date the stock performance stands at 37.01%.
Ironwood Pharmaceuticals (IRWD) : 7 analysts are covering Ironwood Pharmaceuticals (IRWD) and their average rating on the stock is 2.14, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Ironwood Pharmaceuticals (NASDAQ:IRWD): stock was range-bound between the intraday low of $15.71 and the intraday high of $16.165 after having opened at $16.09 on Wednesdays session. The stock finally closed in the red at $16.09, a loss of -1.37%. The stock remained in the red for the whole trading day. The total traded volume was 1,555,082 shares. The stock failed to cross $16.165 in Wednesdays trading. The stocks closing price on Thursday was $16.1.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.